LumiThera said today it inked a distribution deal with Nikon (TYO:7731) subsidiary Optos to distribute its Valeda light delivery system intended for use in treating dry age-related macular degeneration.
The deal will position Optos as the exclusive distributor of the device in 12 European countries, the Seattle-based company said. The device has already won CE Mark approval in the European Union, it added.
“The distribution agreement with Optos allows LumiThera to begin commercialization throughout Europe and establishes a collaboration with a partner in the retinal imaging area. Optos is a global leader in ultra-widefield retinal imaging technologies and we are honored to be working with them to open up a new age in the treatment of AMD,” LumiThera prez & CEO Clark Tedford said in a prepared statement.
Therapy using the Valeda light delivery system consists of a series of light-based treatments to the retinal cells, which LumiThera claims improves energy production and can be used to address inflammation, ischemia and metabolic dysfunction that contribute to the disease.
“Optos is pleased to add the Valeda light delivery system to our product range and to further support eye care professionals to diagnose and manage retinal diseases. This arrangement allows our customers to visualize AMD in the far periphery with color and autofluorescence ultra-widefield retinal imaging and provide a PBM treatment for dry AMD. This is very important for the patients who have this complicated, degenerative disease,” Optos CEO Robert Kennedy said in a press release.